Firmonertinib holds a second-line NSCLC approval; the thesis turns on whether the FURVENT Phase 3 readout unlocks first-line exon 20 insertion labeling

ArriVent BioPharma is a clinical-stage company holding ex-China rights to firmonertinib, a targeted cancer drug for non-small-cell lung cancer with exon 20 insertions; a partner has it approved for second-line treatment in China, but it is not yet approved anywhere in ArriVent's own territory, including the U.S.

Firmonertinib is an EGFR exon 20 insertion-selective TKI with NMPA-approved second-line use in NSCLC and a global Phase 3 FURVENT trial targeting first-line registration. The thesis is determined by whether FURVENT meets its primary endpoint, converting a niche second-line approval into a first-line standard-of-care position. The primary competitive threat is Cullinan's zipalertinib, a direct mechanistic rival in an identical first-line ex20ins NSCLC registration trial, with amivantamab (Rybrevant) already approved in the second-line setting as a structural ceiling.